Ling Yu

430 total citations
13 papers, 356 citations indexed

About

Ling Yu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Ling Yu has authored 13 papers receiving a total of 356 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Oncology. Recurrent topics in Ling Yu's work include Sarcoma Diagnosis and Treatment (5 papers), Angiogenesis and VEGF in Cancer (3 papers) and CAR-T cell therapy research (2 papers). Ling Yu is often cited by papers focused on Sarcoma Diagnosis and Treatment (5 papers), Angiogenesis and VEGF in Cancer (3 papers) and CAR-T cell therapy research (2 papers). Ling Yu collaborates with scholars based in United States, China and Argentina. Ling Yu's co-authors include Eugenie S. Kleinerman, Zhichao Zhou, Laurence J.N. Cooper, Helen Huls, Gangxiong Huang, Nancy Gordon, Dean A. Lee, Krishna Reddy, Bing Su and Jinke Cheng and has published in prestigious journals such as Journal of Biological Chemistry, Cancer and Cancer Research.

In The Last Decade

Ling Yu

12 papers receiving 355 citations

Peers

Countries citing papers authored by Ling Yu

Since Specialization

Citations

This map shows the geographic impact of Ling Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ling Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ling Yu more than expected).

Fields of papers citing papers by Ling Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ling Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ling Yu. The network helps show where Ling Yu may publish in the future.

Co-authorship network of co-authors of Ling Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Ling Yu. A scholar is included among the top collaborators of Ling Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ling Yu. Ling Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	BMSC exosomes deliver JKAP to restore Th17/Treg balance via AKT/ERK, alleviating rheumatoid arthritis 2025 ·iScience ·(unknown), Ling Yu, Heng Wei, Lingzhang Meng, (unknown), Zhonghong Lai, Yuying Huang, (unknown), (unknown), Qingqiong Luo, Jian Song, Qiang Tang, (unknown)	0
2	Aerosol Gemcitabine after Amputation Inhibits Osteosarcoma Lung Metastases but Not Wound Healing 2018 ·Sarcoma ·Eugenie S. Kleinerman, Ling Yu, (unknown), Andrea Hayes‐Jordan, Brock A. Lindsey, Jitesh D. Kawedia, John Stewart, Nancy Gordon	5
3	EWS‐FLI‐1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology 2014 ·Cancer ·Zhichao Zhou, Ling Yu, Eugenie S. Kleinerman	18
4	Aerosol interleukin‐2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis 2014 ·Pediatric Blood & Cancer ·(unknown), Dean A. Lee, Ling Yu, Nancy Gordon, Eugenie S. Kleinerman	34
5	Natural killer cell therapy and aerosol interleukin‐2 for the treatment of osteosarcoma lung metastasis 2013 ·Pediatric Blood & Cancer ·(unknown), Dean A. Lee, Ling Yu, Nancy Gordon, Dennis P.M. Hughes, John Stewart, (unknown), Eugenie S. Kleinerman	37
6	Expression of c‐FLIP in pulmonary metastases in osteosarcoma patients and human xenografts 2012 ·Pediatric Blood & Cancer ·(unknown), (unknown), Ling Yu, Eugenie S. Kleinerman	17
7	Genetically Modified T cells Targeting Interleukin-11 Receptor α-Chain Kill Human Osteosarcoma Cells and Induce the Regression of Established Osteosarcoma Lung Metastases 2011 ·Cancer Research ·Gangxiong Huang, Ling Yu, Laurence J.N. Cooper, (unknown), Helen Huls, Eugenie S. Kleinerman	106
8	Bone marrow cells participate in tumor vessel formation that supports the growth of Ewing’s sarcoma in the lung 2010 ·Angiogenesis ·Zhichao Zhou, (unknown), Ling Yu, Eugenie S. Kleinerman	11
9	Vasculogenesis Driven by Bone Marrow-Derived Cells Is Essential for Growth of Ewing's Sarcomas 2010 ·Cancer Research ·Ling Yu, Bing Su, (unknown), Yong Deng, Valeria Facchinetti, Eugenie S. Kleinerman	19
10	VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing’s sarcoma vasculature 2008 ·Angiogenesis ·Krishna Reddy, Ying Cao, Zhichao Zhou, Ling Yu, (unknown), Eugenie S. Kleinerman	27
11	Suppression of Ewing's Sarcoma Tumor Growth, Tumor Vessel Formation, and Vasculogenesis Following Anti–Vascular Endothelial Growth Factor Receptor-2 Therapy 2007 ·Clinical Cancer Research ·Zhichao Zhou, Marcela F. Bolontrade, Krishna Reddy, Xiaoping Duan, Hui Guan, Ling Yu, Daniel J. Hicklin, Eugenie S. Kleinerman	42
12	The role of MEKK3 in osteosarcoma invasion and metastasis 2006 ·Cancer Research ·Ling Yu, Xiaofang Wang, Robert R. Langley, Hui Guan, (unknown), Bing Su, Eugenie S. Kleinerman	1
13	Dimerization through the Catalytic Domain Is Essential for MEKK2 Activation 2005 ·Journal of Biological Chemistry ·Jinke Cheng, Ling Yu, (unknown), Qiaojia Huang, David M. Spencer, Bing Su	39

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact